HELE · Helen of Troy Limited · Stock research

Current Thesis

Since the last note the tape has moved and the operating record has not. HELE closed $30.22 on 2026-08-14, the highest close of the trailing 52 weeks, after three weeks of chop between the 2026-07-08 low of $25.13 and the 2026-07-28 high of $29.65. Nothing dated explains the break. The most recent company headline is a 2026-08-10 notice of participation in the Canaccord Genuity 46th Annual Growth Conference, which ran 2026-08-11 to 2026-08-13 in Boston; the most recent analyst actions are both 2026-07-09 (UBS Neutral, target $28; Canaccord Hold, target raised to $25 from $23). Consensus was still Hold with a $26.50 average target as of 2026-08-07, so price now sits above every published target on the name.

The narrative leg being bought is the same one that survived the July print: a deleveraging stub. Net leverage 3.48x at 2026-05-31 versus 3.87x at the February year-end, total debt $716.1M versus $871.0M a year earlier, FY2027 free cash flow guided $85–$100M, and a year-end net-leverage target of 3.2x or lower. At 2026-08-14 the equity is $703.89M inside a $1.45B enterprise value with net cash of -$745.67M. Debt retired accrues to the smaller number.

What changed is the price paid for that claim. Forward P/E went from 7.55 on 2026-07-31 to 8.25 on 2026-08-14 while the FY2027 adjusted EPS guide of $3.25–$3.75 sat unchanged. That is multiple expansion without estimate revision — an inference from two dated statistics snapshots, not a company disclosure — and it raises the bar for the ~2026-10-08 Q2 print, which is the next number of consequence.

The narrative is maturing. The deleveraging frame is established and still working in price (+33.7% over three months, new 52-week closing high 2026-08-14), but the attention side has not expanded with it: no analyst action since 2026-07-09, no company news flow in August beyond a conference notice and class-action reminders, and coverage thin enough that the published consensus rests on a two-analyst average. It is not accelerating — there is no fresh headline behind the August leg. It is not saturated — no mainstream coverage, and short interest rose rather than covered.

Bullish and bearish views on Helen of Troy Limited

The model's bull view on Helen of Troy Limited (HELE), in brief: Debt reduction is measured, not promised (2026-07-08): net leverage 3.48x versus 3.87x at the FY2026 close; total debt $716.1M versus $871.0M a year earlier; management put a number on the next step at 3.2x or lower by fiscal year-end. The bear view: The beat was sold (2026-07-08): a double beat — sales $402.1M versus consensus near $374.6M, adjusted EPS $0.17 versus roughly breakeven Margins moved the wrong way (2026-07-08): gross margin 46.0% (-110bp YoY), adjusted operating margin 4.0% (-30bp), adjusted EBITDA margin 6.3%… Both cases follow in full.

Bull Case

• Debt reduction is measured, not promised (2026-07-08): net leverage 3.48x versus 3.87x at the FY2026 close; total debt $716.1M versus $871.0M a year earlier; management put a number on the next step at 3.2x or lower by fiscal year-end.
• Both segments grew in Q1 FY2027 (2026-07-08): Home & Outdoor $194.9M (+9.5%), Beauty & Wellness $207.2M (+7.0%); FY2027 segment guide $859–884M and $900–947M.
• The topline guide was raised into a cautious consumer (2026-07-08): FY2027 net sales lifted to $1.759B–$1.831B, adjusted EPS held at $3.25–$3.75.
• Cash conversion is guided to return (2026-07-08): FY2027 free cash flow $85–$100M after Q1 printed -$6.4M, with roughly $7M of remaining phase-one tariff refunds guided as collectible in the quarter ending 2026-08-31.
• Valuation still carries the case: 8.25x forward on 23.29M shares at 2026-08-14, against FY2026 adjusted EBITDA of $185.8M and a brand set including OXO, Hydro Flask, Osprey, Braun, Vicks and Drybar.
• No open-market insider selling on the 2026 record: CEO G. Scott Uzzell was awarded 109,289 restricted shares on 2026-03-06 (direct holdings to 240,761); CFO Brian Grass had 1,288 shares withheld at $17.64 on 2026-03-01. The Form 4 record shows grants and tax withholding, no sales into the doubling off the $13.85 low.

Bear Case

• The beat was sold (2026-07-08): a double beat — sales $402.1M versus consensus near $374.6M, adjusted EPS $0.17 versus roughly breakeven
• Margins moved the wrong way (2026-07-08): gross margin 46.0% (-110bp YoY), adjusted operating margin 4.0% (-30bp), adjusted EBITDA margin 6.3% versus 6.9%, adjusted EPS $0.17 versus $0.41. Revenue recovered; earnings power did not.
• Price has outrun the sell side: $30.22 at 2026-08-14 against a $26.50 consensus average target (2026-08-07), UBS $28 and Canaccord $25 (both 2026-07-09). The re-rating happened with no published estimate increase behind it.
• Credit quality is not clean: net cash -$745.67M and an Altman Z-Score of 1.9 at 2026-08-14, against $21.7M of cash at the 2026-05-31 quarter end.
• Dilution is on the ballot: the 2026-08-25 AGM includes an amendment increasing shares available under the 2025 Stock Incentive Plan against 23.29M shares outstanding (DEF 14A filed 2026-06-24).
• Litigation runs alongside: the securities class action covering purchases from 2024-04-24 to 2025-10-08 over Project Pegasus disclosures passed its 2026-08-03 lead-plaintiff deadline; the sitting CFO is a named individual defendant.

Setup & Price Structure

The 2026-07-08 through 2026-07-28 range ($25.13–$29.65) has been resolved upward: $30.22 at 2026-08-14 is a fresh 52-week closing high on the adjusted series, and the pipeline's own reference series shows zero distance from that high. The 50-day moving average rose from $27.30 at 2026-07-31 to $27.95 at 2026-08-14; the 200-day rose from $21.15 to $21.64 over the same stretch. Price is roughly 8% above the 50-day and about 40% above the 200-day — extended against the slower line, not against the fast one. RSI(14) at 61.4 is not an overbought reading, which argues the August advance was steady rather than a vertical squeeze.

Crowding and positioning observables, stated as observables: short interest is 2.78M shares, 12.76% of float at the latest report versus 2.70M shares, 11.71% at 2026-07-31 — shorts added into a rising tape rather than covering. Shares outstanding of 23.29M with a five-year beta of 1.30 mean modest volume moves the print. Price trades above the $26.50 consensus average target and above both individually published targets. There is no scheduled earnings date inside 30 days, so the nearest hard event is a governance vote, not a number.

Catalyst Calendar (next 30 days)

• 2026-08-31 — Fiscal Q2 FY2027 quarter-end. The ~$7M balance of phase-one tariff refunds was guided as collectible in this quarter, and this is the balance-sheet date against which the 3.2x year-end leverage path gets measured.
• ~2026-10-08 (est.) — Q2 FY2027 results (prior-year Q2 was reported 2025-10-09). Outside the 30-day window; the first read on whether gross margin stops eroding below 46.0% and whether leverage moved below 3.48x.

Elapsed catalysts

• 2026-08-25 — Virtual annual general meeting, 10:00 a.m. EDT: nine directors, advisory say-on-pay, an amendment increasing shares available under the 2025 Stock Incentive Plan, and ratification of Grant Thornton LLP as FY2027 auditor (DEF 14A filed 2026-06-24). The share-increase vote attaches a number to planned issuance against 23.29M shares outstanding; the say-on-pay tally reads shareholder tolerance after an $899.0M FY2026 net loss. (passed 1d ago)
• Elapsed, for the record: the 2026-08-03 lead-plaintiff deadline and the 2026-08-11 to 2026-08-13 Canaccord Genuity growth conference both came and went without a dated company disclosure. (passed 13d ago)

What Would Change Our Mind

The structure that would have to break first is the August breakout itself: losing the 2026-07-28 pivot at $29.65 and then the rising 50-day line would put the stock back inside the $25.13–$29.65 post-print range and reduce the move to a failed breakout on no news. A daily close below $27.95 is the gradeable version of that.

On fundamentals, the case rests on one variable, and it reports in October. Net leverage flat or above 3.48x at the Q2 FY2027 print, or any reduction to the $85–$100M FY2027 free-cash-flow guide, removes the driver that justifies paying for a $703.89M equity slice inside a $1.45B enterprise value. Gross margin printing below 46.0% again while the $3.25–$3.75 adjusted EPS range is narrowed to its low end would say the topline recovery is being bought with profitability.

Two second-order conditions would also count. If the 2026-08-25 vote approves a large stock-plan increase relative to 23.29M shares outstanding and an S-8 follows, the share count stops being the scarce asset. And if the theme reads saturated — retail-sentiment coverage clustering while the $26.50 consensus target stays put and shorts keep adding above $30 — the marginal buyer is no longer the deleveraging thesis.

Correlation Notes

• With net cash at -$745.67M against a $703.89M market cap (2026-08-14), the equity behaves more like a claim on credit conditions than on quarterly housewares demand. Widening high-yield spreads compress this equity faster than they compress an unlevered small-cap peer — an inference from the capital structure, not a measured beta.
• Beta of 1.30 (five-year, 2026-08-14) with 23.29M shares outstanding: index-level small-cap risk-off flows travel through a thin float.
• Tariff policy is a direct P&L line here, not a macro overlay: gross margin pressure was attributed to tariffs at the 2026-07-08 print, and ~$9.2M of phase-one refunds was built into the FY2027 guide. Changes in duty rates or refund timing show up in the same quarter they occur.
• Sector read-across runs through discretionary housewares and outdoor peers (Newell, Spectrum Brands, YETI) on the demand line, but the leverage profile means HELE can trade against them on the same consumer datapoint.